Floatz logo

Infliximab

Lymphocytes

National Institute of Allergy and Infectious Diseases (NIAID)monoclonal_antibodyPhase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
89/ 100

Competitive context

3 Active assets in the Lymphocytes cohort.

Asset / SponsorPhaseRating
Mesalamine
National Institute of Allergy and Infectious Diseases (NIAID)
Phase 2CCC
MERCAPTOPURINE ANHYDROUS
National Institute of Allergy and Infectious Diseases (NIAID)
Phase 2CCC
TACROLIMUS
National Institute of Allergy and Infectious Diseases (NIAID)
Phase 2CCC
Adalimumab
National Institute of Allergy and Infectious Diseases (NIAID)
Phase 2CCC
Fludarabine
H. Lee Moffitt Cancer Center and Research Institute
Phase 1CC
TIL
H. Lee Moffitt Cancer Center and Research Institute
Phase 1CC
Cyclophosphamide
H. Lee Moffitt Cancer Center and Research Institute
Phase 1CC

Same molecule, other indications

Infliximab is also rated in:

CachexiaDormant
BB
Indicative ·
64 / 100
View asset →
hepatosplenic T-cell lymphomaDormant
BB
Indicative ·
64 / 100
View asset →
colitisDormant
B
Indicative ·
63 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →